

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)	
)	
EVDOKIMOV <i>et al.</i>)	
)	Group Art Unit: 1656
Application No. 10/634,027)	
)	Examiner: Noakes, Suzanne Marie
Filed: August 4, 2003)	
)	Confirmation No. 5050
For: THREE DIMENSIONAL)	
COORDINATES OF HPTPbeta)	

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. § 255 AND 37 C.F.R. § 1.323

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BALLARD SPAHR ANDREWS &
INGERSOLL, LLP
Customer Number 23859

April 27, 2009

Sir:

In accordance with the provisions of 35 U.S.C. § 255 and 37 C.F.R. § 1.323, it is respectfully requested that a Certificate of Correction be issued to correct the above-identified patent. Two (2) copies of the Certificate of Correction are appended. The complete Certificate of Correction involves two (2) pages.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

On the cover page, Item (73) Assignee, please delete the word "Proctor," and substitute the following:

-- Procter --

On the cover page under the section "References Cited," "Other Publications," please insert the following:

-- Wang *et al.*, "Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTP β ," *J. of Biological Chem.*, 267(23) (1992).

Wright *et al.*, "Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute Arterial Injury," *Arterioscler Thromb Vasc.*, 1189-1198 (2000).

Fachinger *et al.*, "Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with the Angiopoietin Receptor Tie-2," *Oncogene*, 18:5948-5953 (1999).

Gaits *et al.*, "Increase in Receptor-Like Protein Tyrosine Phosphatase Activity and Expression Level on Density-Dependent Growth Arrest of Endothelial Cells," *Biochem. J.*, 311:97-103 (1995).

Harder *et al.*, "Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTP β) Using Synthetic Phosphopeptides," *Biochem. J.*, 296:395-401 (1994).

Krueger *et al.*, "Structural Diversity and Evolution of Human Receptor-Like Protein Tyrosine Phosphatases," *The EMBO J.*, 9(10):3241-3252 (1990).

Martin, "3D Database Searching in Drug Design," *J. of Medicinal Chemistry*, 35(12):2145-2154 (1992)

Chanteau *et al.*, "Synthesis of Anthropomorphic Molecules: The NanoPutians," *J. Org. Chem.*, 68:8750-8766 (2003)

Hopkins *et al.*, "Inhibitors of Kinesin Activity from Structure-Based Computer Screening," *Biochemistry*, 39:2805-2814 (2000).

Rarey *et al.*, "A Fast Flexible Docking Method Using an Incremental Construction Algorithm," *J. Mol. Biol.*, 261:470-489 (1996).

Jones *et al.*, "Development and Validation of a Genetic Algorithm for Flexible Docking," *J. Mol. Biol.*, 267:727-748 (1997).

Stahl *et al.*, "Detailed Analysis of Scoring Functions for Virtual Screening," *J. Med. Chem.*, 44:1035-1042 (2001).

Skoichet *et al.*, "Lead Discovery Using Molecular Docking," *Chem. Biology*,
6:439-446 (2002) --

In claim 1, column 53, line 35, please delete the word "mediate" and substitute the
following:

-- mediated --

In claim 2, column 53, line 51, please delete the word "mediate" and substitute the
following:

-- mediated --

In claim 9, column 55, line 17, please delete the word "abiltut" and substitute the
following:

-- ability --

In claim 10, column 56, line 25, please delete the wording "containing" and substitute the
following:

-- contacting --

REMARKS

The requested changes were a result of errors on the part of the Patent Office in that the requested changes were correctly filed in the recordation of the Assignment on December 16, 2003, Applicants' Initial Information Disclosure Statement filed on December 18, 2003, and in the Examiner's Amendment filed January 14, 2009. These errors do not involve changes in the patent so as to constitute new matter or to require reexamination. Applicants therefore respectfully request issuance of a Certificate of Correction.

ATTORNEY DOCKET NO. 01279.0009U1
APPLICATION NO. 10/634,027

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

**BALLARD SPAHR ANDREWS &
INGERSOLL, LLP**

/ Richard S. Echler /
Richard S. Echler
Registration No. 41,006

Customer Number 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Mailing (Print/Type)	Richard S. Echler		
Signature	/ Richard S. Echler /	Date	April 27, 2009

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,507,568
APPLICATION NO. : 10/634,027
ISSUE DATE : March 24, 2009
INVENTOR(S) : EVDOKIMOV *et al.*

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover page, Item (73) Assignee, please delete the word "Proctor," and substitute the following:

-- Procter --

On the cover page, under the section "References Cited," "Other Publications," please insert the following:

--Wang *et al.*, "Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTP β ," *J. Of Biological Chem.*, 267(23) (1992).

Wright *et al.*, "Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute Arterial Injury," *Arterioscler Thromb Vasc.*, 1189-1198 (2000).

Fachinger *et al.*, "Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with the angiopoietin Receptor Tie-2," *Oncogene*, 18:5948-5953 (1999).

Gaits *et al.*, "Increase in Receptor-Like Protein Tyrosine Phosphatase Activity and Expression Level on Density-Dependent Growth Arrest of Endothelial Cells," *Biochem. J.*, 311:97-103 (1995).

Harder *et al.*, "Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTP β) Using Synthetic Phosphopeptides," *Biochem. J.*, 296:395-401 (1994).

Krueger *et al.*, "Structural Diversity and Evolution of Human Receptor-Like Protein Tyrosine Phosphatases," *The EMBRO J.*, 9(10):3241-3252 (1990).

Martin, "3D Database Searching in Drug Design," *J. of Medicinal Chemistry*, 35(12):2145-2154 (1992)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Ballard Spahr Andrews & Ingersoll, LLP
999 Peachtree Street
Suite 1000
Atlanta, GA 30309-3915

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, include gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,507,568
APPLICATION NO. : 10/634,027
ISSUE DATE : March 24, 2009
INVENTOR(S) : EVDOKIMOV *et al.*

(continued)

Chanteau *et al.*, "Synthesis of Anthropomorphic Molecules: The NanoPutians,"
J. Org. Chem., 68:8750-8766 (2003)

Hopkins *et al.*, "Inhibitors of Kinesin Activity from Structure-Based Computer
Screening," *Biochemistry*, 39:2805-2814 (2000).

Rarey *et al.*, "A Fast Flexible Docking Method Using an Incremental
Construction Algorithm," *J. Mol. Biol.*, 261:470-489 (1996).

Jones *et al.*, "Development and Validation of a Genetic Algorithm for Flexible
Docking," *J. Mol. Biol.*, 267:727-748 (1997).

Stahl *et al.*, "Detailed Analysis of Scoring Functions for Virtual Screening," *J.*
Med. Chem., 44:1035-1042 (2001).

Skoichet *et al.*, "Lead Discovery Using Molecular Docking," *Chem. Biology*,
6:439-446 (2002) --

In claim 1, column 53, line 35, please delete the word "mediate" and substitute the following:

-- mediated --

In claim 2, column 53, line 51, please delete the word "mediate" and substitute the following:

-- mediated --

In claim 9, column 55, line 17, please delete the word "abilut" and substitute the following:

-- ability --

In claim 10, column 56, line 25, please delete the wording "containing" and substitute the following:

-- contacting --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Ballard Spahr Andrews & Ingersoll, LLP
999 Peachtree Street
Suite 1000
Atlanta, GA 30309-3915

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, include gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,507,568
APPLICATION NO. : 10/634,027
ISSUE DATE : March 24, 2009
INVENTOR(S) : EVDOKIMOV *et al.*

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover page, Item (73) Assignee, please delete the word "Proctor," and substitute the following:

-- Procter --

On the cover page, under the section "References Cited," "Other Publications," please insert the following:

--Wang *et al.*, "Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTP β ," *J. Of Biological Chem.*, 267(23) (1992).

Wright *et al.*, "Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute Arterial Injury," *Arterioscler Thromb Vasc.*, 1189-1198 (2000).

Fachinger *et al.*, "Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with the angiopoietin Receptor Tie-2," *Oncogene*, 18:5948-5953 (1999).

Gaits *et al.*, "Increase in Receptor-Like Protein Tyrosine Phosphatase Activity and Expression Level on Density-Dependent Growth Arrest of Endothelial Cells," *Biochem. J.*, 311:97-103 (1995).

Harder *et al.*, "Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTP β) Using Synthetic Phosphopeptides," *Biochem. J.*, 296:395-401 (1994).

Krueger *et al.*, "Structural Diversity and Evolution of Human Receptor-Like Protein Tyrosine Phosphatases," *The EMBRO J.*, 9(10):3241-3252 (1990).

Martin, "3D Database Searching in Drug Design," *J. of Medicinal Chemistry*, 35(12):2145-2154 (1992)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Ballard Spahr Andrews & Ingersoll, LLP
999 Peachtree Street
Suite 1000
Atlanta, GA 30309-3915

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, include gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,507,568
APPLICATION NO. : 10/634,027
ISSUE DATE : March 24, 2009
INVENTOR(S) : EVDOKIMOV *et al.*

(continued)

Chanteau *et al.*, "Synthesis of Anthropomorphic Molecules: The NanoPutians,"
J. Org. Chem., 68:8750-8766 (2003)

Hopkins *et al.*, "Inhibitors of Kinesin Activity from Structure-Based Computer
Screening," *Biochemistry*, 39:2805-2814 (2000).

Rarey *et al.*, "A Fast Flexible Docking Method Using an Incremental
Construction Algorithm," *J. Mol. Biol.*, 261:470-489 (1996).

Jones *et al.*, "Development and Validation of a Genetic Algorithm for Flexible
Docking," *J. Mol. Biol.*, 267:727-748 (1997).

Stahl *et al.*, "Detailed Analysis of Scoring Functions for Virtual Screening," *J.*
Med. Chem., 44:1035-1042 (2001).

Skoichet *et al.*, "Lead Discovery Using Molecular Docking," *Chem. Biology*,
6:439-446 (2002) --

In claim 1, column 53, line 35, please delete the word "mediate" and substitute the following:

-- mediated --

In claim 2, column 53, line 51, please delete the word "mediate" and substitute the following:

-- mediated --

In claim 9, column 55, line 17, please delete the word "abilut" and substitute the following:

-- ability --

In claim 10, column 56, line 25, please delete the wording "containing" and substitute the following:

-- contacting --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Ballard Spahr Andrews & Ingersoll, LLP
999 Peachtree Street
Suite 1000
Atlanta, GA 30309-3915

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, include gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.